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Abstract 
 There are over fifty methods which have been described for the 
assessment of immune complexes in sera or plasma. The measurement of 
circulating immune complexes in sera of patients with different diseases has 
been frequently used for the assessment of disease activity for the purposes 
of disease management/therapy and control. Complement 1q (C1q) binding 
assay has been the most widely used. In the present study circulating 
immune complexes (CIC), were measured for the purposes of assessing the 
relationship with the severity of Plasmodium falciparum severe malarial 
anaemia. Three methods were used, with two being C1q-based assays and a 
novel CR1 binding assay. The ability of the methods to discriminate between 
the severe malarial anaemia cases and their controls was assessed with 
reference to a common heat aggregated human IgG standard. The three 
methods used showed a similar trend in detection of levels of CIC in sera and 
all methods showed elevated levels of CIC in sera of severe malarial anaemia 
cases compared to their controls. When the cases were compared to their 
symptomatic controls, the commercial Quidel C1q kit showed a significance 
difference between SA and UM of p = 0.04 while C1q in-house assay 
showed a highly significant difference for the two groups (p = 0.01). CR1 
binding assay also showed a significance difference between SA and UM (p 
= 0.04). When cases were compared to their symptomatic controls, Quidel 
C1q kit had p = 0.001, C1Q in-house assay had p = 0.006 while CR1 binding 
assay had p = 0.01. 
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Their level of detection differed and this can be attributed to different tracing 
principles and the nature or properties of the immune complexes detected. 
From the results it shows that for the screening of CIC in sera, the use of two 
or more methods will enable detection of ICs of various sizes and 
complexities, and the nature of IC should be considered so as to select the 
most appropriate method that will enable a valid assessment to be carried out 
 
Keywords: Severe malarial anaemia, circulating immune complexes, C1q 
binding assay, complement receptor 1, Complement component 3b 
 
Introduction 
 The assessment of immune complexes (ICs) in sera or plasma of 
patients has been employed for purposes of intervention and management of 
diseases associated with generation of high levels of ICs (Krauledat et al., 
1985), which may persist in circulation and thus modify the cause of 
infection. Over fifty methods have been described for the measurement of 
CICs in humans and animals (Jones et al., 1982). Variability in sensitivity, 
complexity, clinical applicability and limited specificity of the available test 
systems complicates the choice of assay used. Thus, it is well known that the 
application of different assay systems for the detection of CIC will lead to 
divergent results due to different biological and/or physical principles. The 
test systems to be used should be based on different detection principles, 
which will permit the detection of ICs of various sizes and complexity 
(Krauledat et al., 1985). 
 Most test systems used are based on the complement system and its 
breakdown products. This is mainly because most ICs share a common 
property in their ability to activate the complement system via classical or 
alternative pathways hence it seems relevant to test its breakdown products. 
Most of these test systems are antigen non-specific and identify the presence 
of ICs by relying on the different physiochemical and biological properties 
of antigen-complexed antibody as opposed to free antibody (Jones et al., 
1982).  C1q binding of ICs is an indication for the classical method of 
complement activation. C1q binds weakly to monomeric IgG1, IgG2, IgG3 
and IgM. Binding is enhanced when the proteins aggregate because of 
heating or antigen binding. The C1qBA detect only those ICs that bind the 
first component of complement. However, C1qBA detects neither ICs with 
non-complement activating antibodies, like IgG4, nor ICs with antibodies 
that activate complement preferentially via the alternative pathway (IgE and 
IgA) (Theofilopoulus, 1980). C1q also interacts preferentially with ICs larger 
than 19S. It has also been shown that C1qBA is less sensitive in measuring 
smaller (antigen excess) than large complexes (antibody excess) and is 
efficient at detecting complexes of intermediate size (between 19S and 7S) 
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(Woodroffe et al., 1977). Solid phase C1qBA is very sensitive (1-10µg/ml 
aggregated human IgG) and has the distinct advantage over fluid phase C1q 
tests in that it is antibody specific and has minimum false positive results 
(Mitchell et al., 1987).  
 Patients with severe malarial anaemia have been shown to have low 
levels of CR1 (Waitumbi et al., 2000). This suggests that complement is 
being activated hence CR1 is being consumed. Since CR1 is required for IC 
clearance, low levels of CR1 lead to high level of CIC. Studies in malaria 
have also suggested that CIC cause hemolysis and/or erythrophagocytosis by 
immune adherence phenomenon through C3b receptors (Mohamed, 1982, 
Waitumbi et al., 2000).  
 The above observations point to the possibility that during P. 
falciparum malaria infection, ICs with the ability to fix complement are 
generated and this could account for hemolysis. So a method, which would 
enable quantification of this portion of ICs, was appropriate.  
 Complement receptor type 1 (CR1, CD35, C3b/C4b receptor) is a 
transmembrane glycoprotein expressed on several circulating cells including 
erythrocytes, neutrophils, monocytes/macrophages, B-lymphocytes and some 
T-lymphocytes (Ahearn and Fearon, 1989). CR1 on erythrocytes binds C3b 
and C4b and this allows erythrocytes to bind complement opsonized immune 
complexes (IC), a phenomenon referred to as immune adherence. This 
phenomenon aids in the transport of CIC from the circulation to the 
reticuloendothelial system including the liver and skin (Miyaike et al., 2002, 
Cosio et al., 1990). This prevents the indiscriminate IC driven complement 
activation that might be associated with tissue injury (Cornacoff et al., 1983, 
Birmingham 1995). This ability of CR1 to bind C3b, which is an opsonin 
and hence is expected to coat ICs, which fix complement, was utilized in this 
study by immobilizing soluble CR1 onto surfaces of Elisa plate wells and 
will capture opsonized ICs out of a test serum. 
 
Materials and Methods 
Study design and patient population  
 This study was reviewed and approved by Kenya National Ethical 
Review Committee. The recruitment of children and study procedures were 
in accordance with the regulations of the Kenya Medical Research Institute. 
Informed consent was obtained from all parents or legal guardians.  
 The study reported here was case-control in design and was interested 
in complicated malaria pathogenesis and whose findings were reported 
earlier (Stoute et al., Mibei et al., 2005).The immune complex measurements 
relied on C1q binding assay for the reported studies. The demographics of 
the cases of severe anaemia (SA) and their controls were reported earlier 
(Stoute et al., 2003, Mibei et al., 2005).  SAs were defined as children with 
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asexual P. falciparum parasitemia by Giemsa-stained blood smear and 
hemoglobin ≤ 5 g/dL, were recruited from the Pediatric Ward of the Nyanza 
Provincial General Hospital (NPGH), Kisumu. The NPGH catchment area is 
a malaria holoendemic region of the Lake Victoria basin, western Kenya.  
Because this study also included a red cell component that was reported 
elsewhere (Stoute el al., 2003), children were excluded if they had a history 
of blood transfusion within three months preceding enrollment. In addition, 
cases were excluded if there was clinical evidence of other concomitant 
infections or malignancy. Controls with uncomplicated clinical malaria, 
matched by age ± 2 months and gender to each SA case, were recruited from 
the outpatient clinic of the hospital where the respective case was enrolled. 
Inclusion criteria for controls were a Giemsa-stained blood smear positive 
for asexual P. falciparum and an axillary temperature ≥ 37.5 oC or, in the 
absence of the latter, two of the following signs or symptoms: 
nausea/vomiting, irritability, poor feeding, myalgias, or headache.  The 
majority (>80%) of the children in the control groups qualified on the basis 
of an axillary temperature >37.5 oC. Exclusion criteria for controls were the 
same as for cases with the addition of any evidence of malaria complication 
manifested by respiratory distress, palmar or conjuctival pallor, hypotension, 
seizures, hemoglobin ≤5 g/dL, or coma.  As part of other ongoing studies 
SAs and their controls were followed at monthly intervals for a period of 3 to 
6 months.  
 
Collection and processing of blood samples 
 For cases, and controls thick and thin blood films were prepared from 
a pinprick blood and stained with Giemsa stain. Diagnosis of P. falciparum 
parasitemia was confirmed microscopically and venous blood was collected 
into microtainers and allowed to clot for 1 hour at room temperature. The 
serum was collected, aliquoted into cryovials and transported to the 
laboratory on dry ice packs and was frozen at –70 °C until use.  
 
Preparation of heat aggregated IgG (AHG) standards 
 AHG was prepared from purified human IgG (Sigma Chemical Co., 
USA). 6.5mg of human IgG was reconstituted in 1ml of phosphate buffered 
saline (Sigma Chemical Co., USA) and this was heated at 63oC for 30 
minutes. AHG was then separated by column chromatography through 
sephacryl S-300 2.6x70cm column (Armesham Pharmacia, Biotech, 
Piscataway, NJ). Fractionation was performed at a flow rate of 3ml/minute 
with 3.5ml fractions collected. 100µl of each fraction was pipetted onto wells 
of a UV microtitre plate. Absorbance was measured at 280nm using a 
Bioassay reader (Perkin Elmer Norwalk CT USA). Optical density values 
were plotted against the fractions and fractions making up peak A (Figure 2) 
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were pooled and protein concentration was measured by protein assay 
(Pierce, Rockford, ILL). 10µl of AHG sample was added to 200µl of the 
Pierce reagent. This was then incubated at 37oC for 30 minutes and optical 
density was read at 562nm using a Bioassay reader (Perkin Elmer Norwalk 
CT USA). Protein concentration was adjusted to 300µg/ml. 
 
Measurement of Circulating Immune Complexes 
C1q Binding Assay 
 To measure CICs, a commercially available kit (Quidel, Berchworth, 
UK) and an in-house-developed assay were used. The commercial kit comes 
pre-coated and ready to use. For the in-house assay, wells of an Immulon HB 
96-well plate (Thermo Labsystems Helsinki, Finland) were coated with 10 
µg/ml C1q (Sigma-Aldrich, St. Louis, MO) in PBS pH 7.4. After overnight 
incubation at 4 °C, the plates were washed with wash buffer (PBS/0.5% 
Tween) and blocked for 1 hour at room temperature with blocking buffer 
(PBS, 0.5% boiled casein, 1% Tween, 0.01% Thimerosal, 20 µg/ml phenol 
red). Aggregated IgG, prepared as described above, was serially diluted in 
PBS to get dilutions from 0-30µg/ml. Each AHG dilution and test sera were 
then diluted to a final dilution of 1:60 in dilution buffer (PBS, 0.5% boiled 
casein, 0.5% Tween, 0.01% Thimerosal, 20 µg/ml phenol red). 100 µl of 
diluted standard and unknown samples were added to duplicate wells and 
incubated for 1 hr at room temperature. The wells were emptied and washed 
with wash buffer x4. HRP-conjugated goat anti-human IgG (Kirkegaard and 
Perry Labs, Baltimore, MD) was diluted 1:5,000 in wash buffer containing 
0.5% boiled casein and 100µl was added to each well followed by 1 hour 
incubation at room temperature. After washing x4, 200 µl of ABTS substrate 
(Kirkegaard and Perry) was added to each well for 45 min followed by 
measurement of OD415nm.  IC level was expressed as µg/ml of aggregated 
human IgG equivalent (AHG Eq.). 
 
CR1 Binding Assay 
 This is a novel assay, Elisa-based developed in-house to measure 
CIC. The assay is based on the property of complement receptor 1 (CR1) to 
bind opsonized immune complexes (Pascual and Shifferli, 1995, Medof et 
al., 1982, Fearon and Ahearn, 1989). Wells of an Immulon HB 96-well plate 
(Thermo labsystems Helsinki, Finland) were coated with 2.5µg/ml CR1 
(AVANT Immunotherapeutics, MA, USA), in PBS pH 7.4. After overnight 
incubation at 4 °C, the plates were washed with wash buffer (PBS/ 0.5% 
Tween) and blocked for 1 hour at room temperature with 300µl blocking 
buffer (PBS, 0.5% boiled casein, 1% Tween, 0.01% Thimerosal, 20 µg/ml 
phenol red).  Aggregated human IgG (AHG) was prepared as previously 
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described for use as standard and was serially diluted in PBS to get dilutions 
from 0-12µg/ml. 10µl of each AHG dilution were then diluted with an equal 
volume of 10% normal human serum and incubated at 37oC for 30 minutes 
and further diluted to3.33% in dilution buffer (PBS, 0.5% boiled casein, 
0.5% Tween, 0.01% Thimerosal, 20 µg/ml phenol red). 10µl of test serum 
was mixed with an equal volume of PBS and then diluted further as for the 
standards above.100 µl of diluted standard and unknown samples were added 
to duplicate wells and incubated for 1 hour at room temperature. The wells 
were emptied and washed with wash buffer x4. HRP-conjugated goat anti-
human IgG (Kirkegaard and Perry Labs, Baltimore, MD) was diluted 1:1,000 
in wash buffer containing 0.5% boiled casein and 100µl was added to each 
well followed by 1 hr incubation at room temperature. After washing x4, 200 
µl of ABTS substrate (Kirkegaard and Perry) was added to each well for 30 
min followed by measurement of OD415nm.  IC level was expressed as µg/ml 
of aggregated human IgG equivalent (AHG Eq.). 
 
Test to confirm CR1-C3b binding  
 To test for CR1-C3b binding, two methods of inhibiting complement 
activation were employed. The standard normal human serum was heat-
inactivated at 56oC for 30 minutes before mixing with AHG standards and 
incubated as described for normal serum above. The second method 
employed the use of EDTA as a complement inhibitor. AHG standards were 
prepared as described above and then 20µl of 0.2M EDTA was added and 
the standards incubated for 30 minutes. The assay then proceeded as for 
normal standards as described above. 
 
Results  
Size distribution of heat aggregated human IgG 
 Sephacryl S-300 gel separated heated human gamma globulins into 
two prominent peaks with distinct molecular sizes (Fig.1). The first peak 
(Peak A) is the fraction containing aggregated gammaglobulins (AHG) and 
the size is around 19S while peak B mostly contains the non-aggregated 
gammaglobulins with a size of about 7S. 
 The fractions making up peak A were pooled and diluted accordingly 
and this is the one used as the standard for the assays. 
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Figure 1: Elution profile of heat aggregated IgG from Sephacryl S-300. The black dots 
represent the fractions; peak A comprises the fractions, which contains aggregated IgG 
while Peak B contains the non-aggregated IgG fractions. 
 
 By using serial dilution of AHG, standard curves for Quidel C1q, in-
house C1q and CR1 binding assays were generated and were used to 
calculate the IC equivalent concentration in the test samples (Figure 2). 
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Figure 2: Standard curves generated by C1q Quidel, C1q in-house and CR1 binding assays 
using AHG dilutions. 
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CR1 binding inhibition tests 
 Heat-inactivating normal human serum eliminated CR1 binding 
completely (Figure 3). This is attributable to the fact that heating at 56oC for 
30 minutes inactivates complement proteins and enzymes. We employed this 
to confirm that CR1 binding assay is actually based on complement 
activation and requires conversion of C3 to C3b, which will coat the Immune 
complexes (here it coats the AHG which simulates the IC). This was also set 
to confirm the specificity of the assay for the signal being observed is 
attributable mainly to CR1-C3b. 
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Figure 3: Figure showing the curves obtained when Normal Human Serum, Heat-inactivated 
Serum and EDTA-treated Serum were incubated with AHG standards. 
 
 EDTA treatment reduced the signal significantly. EDTA is a known 
chelating agent and we used it to demonstrate that CR1-C3b binding requires 
formation of C3 convertase, which will give rise to cleavage of C3 to get 
C3b either in the classical or the alternative pathways of complement 
activation, on which our assay is based. EDTA acts on the bivalent cations 
(Ca2+, Mg2+), which are involved in proteolytic cleavage of various 
complement proteins. It also inhibits enzyme formation.  
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CIC measurement 
 To quantify CIC, a total of 74 study participants were assessed. They 
comprised 28 severe malarial anaemia cases, 26 uncomplicated malaria 
controls and 20 asymptomatic malaria controls. All the three assays showed 
the same trend in their detection. They all discriminated between the cases 
and their controls in terms of the level of CIC in their sera (Figures 4 and 5). 
The commercial Quidel C1q kit showed a significance difference between 
SA and UM (p = 0.04) while C1q in-house assay showed a highly 
significance difference for the two groups (p = 0.01). CR1 binding assay also 
showed a significance difference between SA and UM (p = 0.04). All the 
three methods showed that there was no significance difference between the 
two sets of controls, UM and AC. When the cases were compared to the 
asymptomatic controls, all the three methods showed a significance 
difference. Quidel kit had p = 0.001, C1Q in-house assay had p = 0.006 
while CR1 binding assay had p = 0.01. The level of detection of CIC by CR1 
binding assay was comparatively lower compared to C1q binding assay for 
CR1 binds only ICs that fixes complement. 
CIC assays
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Figure 4: Scatter plots showing the level of Circulating immune Complexes detected by C1q 
Quidel, C1q in-house and CR1 Binding Assays for severe anaemia (SA) patients and their 
uncomplicated malaria (UM) and asymptomatic (AC) controls. The dots represent the 
various study participants for each study group. 
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Figure 5: Box- and whisker plots showing the level of Circulating Immune Complexes 
(CIC) detected by C1q Quidel, C1q in-house and CR1 Binding Assays for severe anaemia 
(SA) patients and their uncomplicated malaria (UM) and asymptomatic (AC) controls. The 
box represents the interquartile range and the central 50% of the data values fall within the 
range of the box, the black horizontal line in the middle of the box marks the median while 
the gray horizontal line represents the mean of the data. The whiskers are the vertical lines 
extending up and down from each box and represents the upper and the lower 25% of data, 
respectively. 
 
Discussion 
 This study investigated the relationship between circulating immune 
complexes (CICs), and severe P. falciparum malarial anaemia (SA). CICs 
were quantified using C1q and CR1 binding assays. The data generated from 
the two methods shows that serum of P. falciparum malaria patients with SA 
contains higher levels of CIC than their respective age and gender-matched 
controls. C1q binding assay detected higher levels of CIC compared to CR1 
Elisa. This can be said to be due to the detection nature of C1q method, it 
detects a wide range of CIC, and its specificity has been shown to be higher 
(Stanilova and Slavov, 2001, Mitchel et al., 1987). C1q was chosen because 
it is the most widely used antigen non-specific CIC quantitative assessment 
assay hence its properties, like its specificity, have been widely studied. It 
thus formed the best reference for our novel assay. 
 C1q and CR1 assays both showed the same trend of detection but the 
level of CIC detected by CR1 Elisa was comparatively lower than that 
detected by C1q and this could be attributed to the smaller fraction of CIC 
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detected by CR1 assay, those that fix complement or the opsonized CIC 
only. This can also be explained by looking at the properties of the 
complement proteins detected by CR1 assay, C3b and C4b, they are short 
lived in circulation. C3b is inactivated by factor I to inactivated C3b (C3bi) 
(which binds weakly to CR1), and then to C3dg, which is the final 
degradation product (Kazatchkine and Fearon, 1990, Medof et al., 1982). 
This means that an IC opsonized with C3b first binds to a cell bearing CR1 
and at a later stage is released due to C3b degradation (Pascual and Shifferli, 
1995, Davies 1990). This has got an implication for CR1 binding assay; it 
has to be performed as soon as possible after the sample has been obtained in 
order to capture a higher range of complement fixing ICs when C3b is still 
intact. Incubation periods should also be made shorter to minimize the risk of 
further complement activation. CR1 also binds C4b and to a lesser extend 
C3bi, the immediate degradation product of C3b, but has no affinity for 
C3dg (Pascual and Shifferli, 1995).  
 The choice of detection antibody was carefully done to minimize 
instances of false positive results for it only targets the human antibody 
constituting the immune complex, and not the free C3b or C4b or C3bi. So 
the risk of targeting these free or complexed complement proteins has been 
minimized hence specificity improved, but in spite of this there lies a 
possibility of modifying this method to use it as a measure of complement 
activation by targeting C3b/C4b/C3bi, either free or complexed, by having a 
primary antibody which targets these complement proteins then detecting 
with the appropriate detection antibody.  
 In this study, the findings shows elevated levels of CIC in severe 
malarial anaemia cases, and this has been an area of intense research and has 
generated a lot of interest as to the link between generation of ICs, hemolysis 
and its role in pathogenesis of malarial anaemia (Waitumbi et al., 2000, 
Mohamed 1982, Jhaveri et al., 1997, Stoute et al., 2003, Shepherd et al., 
1982, Adam et al., 1981, Mibei et al., 2008). 
 
Conclusion 
 CR1 binding assay presents a possibility of assessing a disease 
associated with intense complement activation for it targets that portion of 
ICs which fix complement and this could be of importance in management of 
such diseases as auto immune diseases and even malaria. The use of CR1 
binding assay as a method of measuring CIC is highly appropriate in diseases 
known to be associated with complement activation and disease pathogenesis 
is known to involve immune adherence, hemolysis or erythrophagocytosis 
like P. falciparum malaria for it gives the actual picture of the CIC fraction 
which could be responsible for disease progression.  
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